All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

@drkopelman's hair loss medication claims, fact-checked

Dr Kopelman 212 470 4076

TikTok creator

9.5K viewsWatch on TikTok→

Quick answer

Minoxidil discontinuation can precipitate a telogen effluvium-like shedding event due to sudden loss of anagen-phase prolongation, an effect documented in clinical literature since the late 1980s. Finasteride and dutasteride withdrawal results in DHT returning to pre-treatment baseline, which resumes androgenetic alopecia progression, but does not produce supraphysiological DHT levels. No randomized controlled trial data currently supports a specific tapering protocol for either drug class as superior to structured discontinuation.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @drkopelman actually say?

The claim here is straightforward: stop minoxidil or finasteride abruptly and your hair will pay for it fast. Specifically, they warn that quitting minoxidil cold turkey triggers "a telogen effluvium state" where mass shedding follows because the drug's growth-phase extension is suddenly removed. For finasteride and dutasteride, the argument is that stopping causes "a spike in DHT" that accelerates follicle miniaturization quickly.

The creator recommends gradual tapering rather than abrupt discontinuation as the fix. That's the full argument. It's brief, it sounds authoritative, and it's mostly pointed in the right direction, but some of the framing needs unpacking.

Does the science back this up?

Largely yes, though the "DHT spike" framing for finasteride is where the evidence gets murkier. The minoxidil withdrawal shedding phenomenon is real and reasonably well-documented. A 1987 study by Olsen et al. in the Journal of the American Academy of Dermatology observed accelerated hair loss within weeks of minoxidil discontinuation in patients who had responded to treatment. The mechanism is biologically coherent: minoxidil prolongs the anagen (growth) phase, and its sudden absence allows follicles to rapidly shift into telogen (resting/shedding) phase en masse.

For finasteride, the picture is slightly different. Finasteride's half-life is roughly five to six hours, and DHT levels do rebound after stopping, but calling it a "spike" implies levels exceed pre-treatment baseline, which isn't consistently supported in the literature. Traish et al. (2011, Journal of Sexual Medicine) and subsequent work suggest DHT returns to baseline rather than surpassing it. So the word "spike" is doing some unearned work here.

What did they get wrong (or right)?

They got the minoxidil withdrawal shedding right. The concept that removing an anagen-prolonging agent causes synchronous telogen shift is supported by clinical observation and mechanistic logic. Credit where it's due.

Where they slipped up is the "spike in DHT" claim for finasteride discontinuation. Serum DHT returns to pre-treatment baseline after stopping finasteride, typically within one to two weeks. It doesn't overshoot. Framing it as a spike implies levels go above where you started, which could mislead patients into thinking their hair situation becomes worse than it ever was before treatment. That's not what the evidence shows.

They also named the condition "telogen of fluvian," which is clearly a spoken-word mishearing of telogen effluvium. That's a minor verbal stumble, but in a medical context, precision matters. If a patient Googles "telogen of fluvian," they find nothing useful.

  • Minoxidil withdrawal shedding: well-supported, claim is accurate
  • Finasteride DHT "spike": overstated, should be "return to baseline"
  • Tapering recommendation: reasonable, though no RCT data exists specifically for tapering protocols

What should you actually know?

If you're on minoxidil and considering stopping, the withdrawal shedding is real enough that dermatologists generally advise against abrupt discontinuation if you've seen meaningful regrowth. The shed typically begins within weeks and can last a few months before the hair stabilizes at roughly where it would have been without treatment. You don't lose extra hair permanently, but it can be jarring.

For finasteride or dutasteride, your DHT will recover to baseline after stopping, not skyrocket past it. The follicle miniaturization that was being suppressed will resume, but you're returning to your genetic trajectory, not accelerating past it. The advice to taper is reasonable as a practical strategy, but there's no controlled trial evidence proving a specific tapering schedule prevents shedding better than a structured stop.

One thing this video doesn't address: some patients who stop finasteride report a subjective worsening that feels rapid. Whether that's DHT rebound kinetics or the resumption of pre-existing loss is clinically hard to separate without baseline photography. Talk to a dermatologist who can compare your actual hair density over time rather than relying on what it feels like day to day.

Bottom line: is this video worth your trust?

It's directionally correct and the core warning is useful. Quitting minoxidil abruptly without a plan is a real clinical issue and the video does patients a service by flagging it. The finasteride "spike" claim is an overstatement that should have been more precise. Overall, this is a reasonable but imperfect clinical caution from a creator who appears to understand the basics. Verify the details with your prescribing provider before making any changes to your regimen.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

TRT social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drkopelman's hair loss medication claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@drkopelman's hair loss medication claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this testosterone and trt video claims cluster

Best for searchers turning TRT social claims into a safer lab-backed provider discussion.

Claim verdict

The useful answer behind this video

Claim being checked

Minoxidil discontinuation can precipitate a telogen effluvium-like shedding event due to sudden loss of anagen-phase prolongation, an effect documented in clinical literature since the late 1980s.

FormBlends verdict

Minoxidil discontinuation can precipitate a telogen effluvium-like shedding event due to sudden loss of anagen-phase prolongation, an effect documented in clinical literature since the late 1980s. Finasteride and dutasteride withdrawal results in DHT returning to pre-treatment baseline, which resumes androgenetic alopecia progression, but does not produce supraphysiological DHT levels. No randomized controlled trial data currently supports a specific tapering protocol for either drug class as superior to structured discontinuation.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Minoxidil discontinuation can precipitate a telogen effluvium-like shedding event due to sudden loss of anagen-phase prolongation, an effect documented in clinical literature since the late 1980s. Finasteride and dutasteride withdrawal results in DHT returning to pre-treatment baseline, which resumes androgenetic alopecia progression, but does not produce supraphysiological DHT levels. No randomized controlled trial data currently supports a specific tapering protocol for either drug class as superior to structured discontinuation.
  • Minoxidil withdrawal shedding is documented since at least Olsen et al. 1987 and can begin within 2 to 4 weeks of abrupt discontinuation.
  • DHT levels after stopping finasteride return to pre-treatment baseline, typically within 1 to 2 weeks, based on the drug's 5 to 6 hour half-life and pharmacokinetic data.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Minoxidil withdrawal shedding is documented since at least Olsen et al. 1987 and can begin within 2 to 4 weeks of abrupt discontinuation.
  • DHT levels after stopping finasteride return to pre-treatment baseline, typically within 1 to 2 weeks, based on the drug's 5 to 6 hour half-life and pharmacokinetic data.
  • No randomized controlled trial currently supports a specific tapering schedule for minoxidil or finasteride as clinically superior to structured discontinuation.
  • Androgenetic alopecia progression resumes after stopping 5-alpha reductase inhibitors, but evidence does not support the idea that hair loss accelerates beyond the pre-treatment trajectory.
  • Telogen effluvium from minoxidil withdrawal is typically temporary. Hair tends to stabilize at roughly the density expected without treatment, not below it.
  • Patients considering stopping either medication should consult a dermatologist who can compare baseline and current hair density documentation rather than relying on perceived changes.
  • The verbal term 'telogen of fluvian' used in the video is a mispronunciation of telogen effluvium, the correct clinical term for synchronous resting-phase hair shedding.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Kopelman 212 470 4076 · TikTok creator

9.5K views on this video

Stop Hair Loss Medications Too Fast And Your Hair May Shock You ⚠️ One of the biggest mistakes I see is people stopping hair loss treatment all at once. If you stop cold turkey, your hair can react qu

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Kopelman 212 470 4076, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.